Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Isoniazid

FDA-approved product (tablet, oral), marketed as Dow-Isoniazid, Hyzyd, Inh and 5 more.

Registered studies
50+
Lab records
268
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Isoniazid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Pulmonary tuberculosis
  • Silicosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hydrazides
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AC01; WHO ATC J04AC51; FDA class Antimycobacterial

Repurposing investigation

Isoniazid is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA8.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli7.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae3.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 241 of 268 lab records
Open Isoniazid in ChEMBL Registered studies below
Show the latest 150 of 268 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Isoniazid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetic Study of Linezolid for TB Meningitis

    NCT03537495 · start 2021-06-21

    Registered record
    Registry ID
    NCT03537495
    Conditions
    Tuberculosis, Meningeal; Linezolid
    Interventions
    Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-06-21
    Completion
    2023-07-20
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Meningeal; Linezolid
    InterventionLinezolid
    PhasePhase 2
    Registry statusCompleted

  • Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis

    NCT04176250 · start 2020-01-16

    Registered record
    Registry ID
    NCT04176250
    Conditions
    Pulmonary Tuberculosis
    Interventions
    TBA-7371; TBA-7371; TBA-7371; TBA-7371; TBA-7371; HRZE
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-01-16
    Completion
    2022-10-05
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionTBA-7371; TBA-7371; TBA-7371; TBA-7371 +2 more
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy

    NCT03982277 · start 2019-04-30

    Registered record
    Registry ID
    NCT03982277
    Conditions
    Tuberculosis
    Interventions
    Rifampin 300 Mg Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-04-30
    Completion
    2021-07-23
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifampin 300 Mg Oral Capsule
    PhasePhase 2
    Registry statusCompleted

  • Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults

    NCT05283967 · start 2019-01-01

    Registered record
    Registry ID
    NCT05283967
    Conditions
    Tuberculosis
    Interventions
    urine colorimetric assay
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-01-01
    Completion
    2023-12-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionurine colorimetric assay
    PhaseNot recorded
    Registry statusCompleted

  • The Individualized M(X) Drug-resistant TB Treatment Strategy Study

    NCT03237182 · start 2017-06-14

    Registered record
    Registry ID
    NCT03237182
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Individualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-06-14
    Completion
    2022-12-19
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionIndividualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    PhasePhase 4
    Registry statusTerminated

  • Efficacy and Safety of Intravenous Treatment of Tuberculosis

    NCT04150367 · start 2017-03-03

    Registered record
    Registry ID
    NCT04150367
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Isoniazid; Rifampicin; Ethambutol; Rifampicin; Isoniazid; Ethambutol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2017-03-03
    Completion
    2018-07-14
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionIsoniazid; Rifampicin; Ethambutol; Rifampicin +2 more
    PhaseNot recorded
    Registry statusTerminated

  • Improving the Management of Drug Resistant Tuberculosis in the UK

    NCT02875574 · start 2016-11

    Registered record
    Registry ID
    NCT02875574
    Conditions
    Tuberculosis
    Interventions
    Any treatment regimen; Bacterial mutation
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-11
    Completion
    2017-12
    Enrolment
    630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionAny treatment regimen; Bacterial mutation
    PhaseNot recorded
    Registry statusCompleted

  • Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

    NCT02901288 · start 2016-08

    Registered record
    Registry ID
    NCT02901288
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Isoniazid; Rifampicin; Pyrazinamide; Ethambutol; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-08
    Completion
    2018-12
    Enrolment
    3,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionIsoniazid; Rifampicin; Pyrazinamide; Ethambutol +1 more
    PhasePhase 4
    Registry statusUnknown

  • VDOT for Monitoring Adherence to LTBI Treatment

    NCT02641106 · start 2016-03-08

    Registered record
    Registry ID
    NCT02641106
    Conditions
    Tuberculosis; Latent Tuberculosis Infection
    Interventions
    Video Directly Observed Therapy; In-Person DOT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-03-08
    Completion
    2020-06-30
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Latent Tuberculosis Infection
    InterventionVideo Directly Observed Therapy; In-Person DOT
    PhaseNot applicable
    Registry statusCompleted

  • TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

    NCT02410772 · start 2016-01-25

    Registered record
    Registry ID
    NCT02410772
    Conditions
    Tuberculosis
    Interventions
    rifapentine; rifapentine and moxifloxacin; control
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-05
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionrifapentine; rifapentine and moxifloxacin; control
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

    NCT02563327 · start 2016-01-25

    Registered record
    Registry ID
    NCT02563327
    Conditions
    Tuberculosis
    Interventions
    Rifapentine; Moxifloxacin; Rifampin; Isoniazid; Pyrazinamide; Ethambutol; Pyridoxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-08-30
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine; Moxifloxacin; Rifampin; Isoniazid +3 more
    PhasePhase 3
    Registry statusCompleted

  • Preventing Childhood Tuberculosis in Lesotho (PREVENT Study)

    NCT02662829 · start 2015-12

    Registered record
    Registry ID
    NCT02662829
    Conditions
    Tuberculosis
    Interventions
    Community-based intervention; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-12
    Completion
    2019-01
    Enrolment
    562

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionCommunity-based intervention; Standard of care
    PhaseNot applicable
    Registry statusCompleted

  • IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

    NCT02383849 · start 2015-08-04

    Registered record
    Registry ID
    NCT02383849
    Conditions
    Low-Birth-Weight Infant; Tuberculosis; HIV
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-08-04
    Completion
    2020-02-14
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow-Birth-Weight Infant; Tuberculosis; HIV
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Impact of Nursing Interventions on Adherence to Treatment With Anti-tuberculosis Drugs in Children and Adolescents

    NCT03230409 · start 2014-01-01

    Registered record
    Registry ID
    NCT03230409
    Conditions
    Tuberculosis
    Interventions
    Leaflet written in the patient's/family mother tongue; A follow-up telephone call; Eidus-Hamilton Test; A written questionnaire
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-01-01
    Completion
    2017-01-15
    Enrolment
    359

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionLeaflet written in the patient's/family mother tongue; A follow-up telephone call; Eidus-Hamilton Test; A written questionnaire
    PhaseNot applicable
    Registry statusCompleted

  • Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

    NCT01601626 · start 2013-07-13

    Registered record
    Registry ID
    NCT01601626
    Conditions
    HIV Infection; Tuberculosis
    Interventions
    Standard-dose Lopinavir/Ritonavir; Double-dose Lopinavir/Ritonavir; Raltegravir; Isoniazid; Pyridoxine; Pyrazinamide; Ethambutol; Rifabutin; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-07-13
    Completion
    2017-06-28
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Tuberculosis
    InterventionStandard-dose Lopinavir/Ritonavir; Double-dose Lopinavir/Ritonavir; Raltegravir; Isoniazid +5 more
    PhasePhase 2
    Registry statusTerminated